In 2004, a vascular endothelial growth factor (VEGF)-specific aptamer, Macugen, was first approved by the Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration (AMD), which indeed has opened up new possibilities in the field of aptamers [21]. Here, VEGFA is linked to age-related macular degeneration.